8-K: Bausch + Lomb Q1 2026 Results Exceed Expectations, Guidance Raised

Bausch + Lomb Corporation reported strong first-quarter 2026 results, with revenue up 9% and a significant improvement in operating income, leading to a raised full-year guidance.

Summary

• Bausch + Lomb Corporation announced first-quarter 2026 results, with total revenue reaching $1.244 billion, a 9% increase compared to $1.137 billion in the first quarter of 2025.
• On a constant currency basis, revenue grew 6% year-over-year.
• The company reported a GAAP Net Loss of $71 million for the quarter, an improvement from a $212 million net loss in Q1 2025.
• Adjusted EBITDA (non-GAAP) was $189 million, up from $98 million in the prior year's quarter.
• Adjusted EBITDA excluding Acquired IPR&D (non-GAAP) was $200 million.
• The company is raising its full-year 2026 guidance for both revenue and Adjusted EBITDA Excluding Acquired IPR&D.
• Key growth drivers included the dry eye portfolio, premium intraocular lenses, and daily SiHy contact lenses, with Pharmaceuticals segment revenue up 14% driven by MIEBO and XIIDRA.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, with significant revenue growth, improved profitability, and raised guidance, indicating robust business performance and positive future prospects.

Positives

• Total revenue increased by 9% to $1.244 billion in Q1 2026 compared to $1.137 billion in Q1 2025.
• Constant currency revenue growth was 6% for the quarter.
• Operating income improved significantly to $33 million from an operating loss of $83 million in the prior year.
• GAAP Net Loss narrowed to $71 million from $212 million in Q1 2025.
• Adjusted EBITDA (non-GAAP) more than doubled to $189 million from $98 million in Q1 2025.
• Adjusted EBITDA excluding Acquired IPR&D (non-GAAP) increased to $200 million from $126 million.
• Pharmaceuticals segment revenue saw strong growth of 14%, with MIEBO up 33% and XIIDRA up 30%.
• Full-year 2026 revenue and Adjusted EBITDA Excluding Acquired IPR&D guidance has been raised.

Negatives

• The company reported a GAAP Net Loss of $71 million for the first quarter of 2026.
• Amortization of intangible assets was $57 million in Q1 2026.

Risks

• The company's forward-looking statements are subject to risks and uncertainties, including those discussed in its SEC and CSA filings.
• Risks related to the proposed separation of Bausch + Lomb into an independent company, including expected benefits, costs, and timing.
• Potential impact of tariffs imposed by the U.S. and counter-tariffs, and disruptions to global supply chains.
• Risks associated with adopting and integrating artificial intelligence solutions.
• Adverse economic conditions and macroeconomic factors, including those related to the conflict in the Middle East, heightened inflation, and interest rates.
• Risks related to acquisitions and business development transactions, including potential failure to close or realize expected benefits.
• The company cannot assure that the separation will occur or on the terms anticipated.

Future Outlook

The company has raised its full-year 2026 guidance. Full-Year Revenue is now projected to be between $5.420 billion and $5.520 billion, representing 5.3% to 7.2% constant currency growth. Full-Year Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP) is now projected to be between $1.010 billion and $1.060 billion.

Management Comments

• "We're doing exactly what we said we would: driving sustainable growth and margin expansion, improving how we sell and operate and continuing to invest in a pipeline that will carry us forward," said Brent Saunders, chairman and CEO, Bausch + Lomb.
• The company highlights growth across key brands, including the dry eye portfolio, premium intraocular lenses, and daily SiHy contact lenses.
• Double-digit revenue growth in Pharmaceuticals was driven by MIEBO (+33%) and XIIDRA (+30%).
• PreserVision AREDS3 and Blink Triple Care Preservative Free U.S. launches are underway.
• Advanced R&D milestones include the LUMIFY NXT NDA filing and seeLYRA CE submission completion.
• Broad AI adoption is helping drive operational efficiencies across the business.

Industry Context

StockSavvy.ai notes that Bausch + Lomb's performance in Q1 2026, particularly the strong revenue growth and improved profitability, aligns with a broader trend of recovery and innovation within the eye health sector. The company's focus on key growth areas like dry eye and premium IOLs, coupled with advancements in pharmaceuticals, positions it well against competitors.

Comparison to Industry Standards

• The 9% reported revenue growth and 6% constant currency growth for Q1 2026 surpasses the typical growth rates seen in the broader medical device and pharmaceutical sectors, which often range from 3-7% annually.
• The significant improvement in operating income and Adjusted EBITDA indicates strong operational leverage, a key performance indicator that many competitors strive for but do not always achieve due to market pressures or R&D investments.
• The double-digit growth in the Pharmaceuticals segment, driven by specific products like MIEBO and XIIDRA, is particularly noteworthy and suggests Bausch + Lomb is outperforming competitors in specific therapeutic areas within eye care.

Stakeholder Impact

• Shareholders: Positive impact expected due to raised guidance and improved financial performance, potentially leading to increased stock value.
• Employees: Continued investment in R&D and AI adoption may lead to new opportunities and operational efficiencies.
• Customers: Continued product innovation and launches in key areas like dry eye and contact lenses benefit customers.
• Suppliers: Increased demand from revenue growth may positively impact suppliers.

Next Steps

• Continue driving sustainable growth and margin expansion.
• Improve sales and operational processes.
• Continue investing in the product pipeline.
• Complete U.S. launches for PreserVision AREDS3 and Blink Triple Care Preservative Free.
• Monitor and manage the impact of tariffs and global supply chain developments.
• Integrate AI solutions across business operations.

Key Dates

Recommendation

The company demonstrated strong Q1 2026 performance with significant revenue growth, a substantial improvement in profitability, and raised full-year guidance. Key product lines are performing exceptionally well, and strategic initiatives like AI adoption are yielding results. The positive outlook and execution suggest a compelling investment opportunity.

Keywords

Bausch + Lomb, Eye Health, Q1 2026 Results, Revenue Growth, Adjusted EBITDA, Pharmaceuticals, Vision Care, Surgical